Evidence map›Paper›PMID 34297922›Full record

ArticleCell host & microbe2021

Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease.

Jonathan Wei Jie Lee, Damian Plichta, Larson Hogstrom, Nynke Z Borren, Helena Lau, Sara M Gregory, William Tan, Hamed Khalili, Clary Clish, Hera Vlamakis and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell host & microbe, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 147 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
147citing papers in PubMed, 5 pooled it
23.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

147 citing papers in PubMed, 5 syntheses or guidelines pooled it, 208 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Observational
  20. Article

87 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Jonathan Wei Jie LeeBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, Singapore 119228, Singapore; Division of Gastroenterology and Hepatology, National University Health System, Singapore University Medical Center, 5 Lower Kent Ridge Rd, Singapore 119074, Singapore; NUS Synthetic Biology for Clinical and Technological Innovation (SynCTI), 14 Medical Drive, MD6-Centre for Translational Medicine, Singapore 117599, Singapore.
Damian PlichtaBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Larson HogstromBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Nynke Z BorrenDivision of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, USA.
Helena LauBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Division of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, USA.
Sara M GregoryDivision of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, USA.
William TanDivision of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, USA.
Hamed KhaliliDivision of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, USA.
Clary ClishBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Hera VlamakisBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Ramnik J XavierBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Microbiome Informatics and Therapeutics, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Center for Computational and Integrative Biology and Department of Molecular Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. Electronic address: xavier@molbio.mgh.harvard.edu.
Ashwin N AnanthakrishnanDivision of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, USA. Electronic address: aananthakrishnan@mgh.harvard.edu.
Massachusetts General Hospital · USBroad Institute · USMassachusetts Institute of Technology · US

Funding

RP5: Chemical proteomic discovery of small-molecule probes for autophagy proteinsU19AI142784 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI VIRGIN, HERBERT W · 2019 to 2023
$36.9M
Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1991 to 2026
$35.3M
The importance of the IgG4 glycome in IgG4-related disease(s)U19AI110495 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Ramnik J Xavier · 2014 to 2026
$7.9M
Identification and characterization of gut microbial bioactive molecules that determine predisposition to autoimmune disease and atopyR01AT009708 · NCCIH · HARVARD MEDICAL SCHOOL · PI CLARDY, JON, XAVIER, RAMNIK J · 2017 to 2021
$3.3M
Differential impact of smoking on the transcriptome and epigenome in Crohn's disease and ulcerative colitis"R21DK127227 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI ANANTHAKRISHNAN, ASHWIN N · 2020 to 2021
$369k
NCCIH NIH HHS R01 AT009708NIAID NIH HHS U19 AI110495NIAID NIH HHS U19 AI142784NIDDK NIH HHS P30 DK043351NIDDK NIH HHS R21 DK127227
6 · The paper itself

Abstract

The intestinal microbiome is a key determinant of responses to biologic therapy in inflammatory bowel disease (IBD). However, diverse therapeutics and variable responses among IBD patients have posed challenges in predicting clinical therapeutic success. In this prospective study, we profiled baseline stool and blood in patients with moderate-to-severe Crohn's disease or ulcerative colitis initiating anti-cytokine therapy (anti-TNF or -IL12/23) or anti-integrin therapy. Patients were assessed at 14 weeks for clinical remission and 52 weeks for clinical and endoscopic remission. Baseline microbial richness indicated preferential responses to anti-cytokine therapy and correlated with the abundance of microbial species capable of 7α/β-dehydroxylation of primary to secondary bile acids. Serum signatures of immune proteins reflecting microbial diversity identified patients more likely to achieve remission with anti-cytokine therapy. Remission-associated multi-omic profiles were unique to each therapeutic class. These profiles may facilitate a priori determination of optimal therapeutics for patients and serve as targets for newer therapies.

Indexed as

Biological TherapyInflammatory Bowel DiseasesAntibodies, Monoclonal, HumanizedBiomarkersBloodColitis, UlcerativeCrohn DiseaseCytokinesFecesGastrointestinal MicrobiomeHumansInfliximabMetabolomicsMetagenomeProspective StudiesProteomicsAntibodies, Monoclonal, HumanizedBiomarkersCytokinesInfliximabTumor Necrosis Factor InhibitorsvedolizumabbiologicsCrohn's diseaseinflammatory bowel diseaseinfliximabmetabolomicsmicrobiomemulti-omicsproteomicsremissionvedolizumab

Identifiers

PMID34297922
PMCPMC8366279
OpenAlexW3183860390

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.